Literature DB >> 21245273

Primary human colonic myofibroblasts are resistant to Clostridium difficile toxin A-induced, but not toxin B-induced, cell death.

N Mullan1, K R Hughes, Y R Mahida.   

Abstract

Colonic inflammation in Clostridium difficile infection is mediated by released toxins A and B. We investigated responses to C. difficile toxins A and B by isolated primary human colonic myofibroblasts, which represent a distinct subpopulation of mucosal cells that are normally located below the intestinal epithelium. Following incubation with either purified toxin A or B, there was a change in myofibroblast morphology to stellate cells with processes that were immunoreactive for alpha-smooth muscle actin. Most of the myofibroblasts remained viable, with persistence of stellate morphology, despite exposure to high concentrations (up to 10 μg/ml) of toxin A for 72 h. In contrast, a majority of the toxin B-exposed myofibroblasts lost their processes prior to cell death over 24 to 72 h. At low concentrations, toxin A provided protection against toxin B-induced cell death. Within 4 h, myofibroblasts exposed to either toxin A or toxin B lost expression of the nonglucosylated form of Rac1, and there was also a loss of the active form of RhoA. Despite preexposure to high concentrations of toxin A for 3 h, colonic myofibroblasts were able to recover their morphology and proliferative capacity during prolonged culture in medium. However, toxin B-preexposed myofibroblasts were not able to recover. In conclusion, primary human colonic mucosal myofibroblasts are resistant to toxin A (but not toxin B)-induced cell death. Responses by colonic myofibroblasts may play an important role in mucosal protection, repair, and regeneration in colitis due to C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245273      PMCID: PMC3067538          DOI: 10.1128/IAI.00686-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Early functional effects of Clostridium difficile toxin A on human colonocytes.

Authors:  J E Branka; G Vallette; A Jarry; C Bou-Hanna; P Lemarre; P N Van; C L Laboisse
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

2.  Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies.

Authors:  D M Lyerly; C J Phelps; J Toth; T D Wilkins
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

3.  Villus contraction aids repair of intestinal epithelium after injury.

Authors:  R Moore; S Carlson; J L Madara
Journal:  Am J Physiol       Date:  1989-08

4.  Purification and properties of Clostridium difficile cytotoxin B.

Authors:  C Pothoulakis; L M Barone; R Ely; B Faris; M E Clark; C Franzblau; J T LaMont
Journal:  J Biol Chem       Date:  1986-01-25       Impact factor: 5.157

5.  Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment.

Authors:  Y R Mahida; S Makh; S Hyde; T Gray; S P Borriello
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

6.  Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts.

Authors:  M Bajaj-Elliott; E Breese; R Poulsom; P D Fairclough; T T MacDonald
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  Inactivation of the small GTP binding protein Rho induces multinucleate cell formation and apoptosis in murine T lymphoma EL4.

Authors:  J P Moorman; D A Bobak; C S Hahn
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

8.  Purification and characterisation of Clostridium difficile toxin A by bovine thyroglobulin affinity chromatography and dissociation in denaturing conditions with or without reduction.

Authors:  S Kamiya; P J Reed; S P Borriello
Journal:  J Med Microbiol       Date:  1989-09       Impact factor: 2.472

9.  Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers.

Authors:  G Hecht; C Pothoulakis; J T LaMont; J L Madara
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

10.  Purification and characterization of toxin B from Clostridium difficile.

Authors:  J Meador; R K Tweten
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

View more
  5 in total

1.  Isolation of CD 90+ Fibroblast/Myofibroblasts from Human Frozen Gastrointestinal Specimens.

Authors:  Paul Johnson; Ellen J Beswick; Celia Chao; Don W Powell; Mark R Hellmich; Iryna V Pinchuk
Journal:  J Vis Exp       Date:  2016-01-31       Impact factor: 1.355

2.  Using phenotype microarrays to determine culture conditions that induce or repress toxin production by Clostridium difficile and other microorganisms.

Authors:  Xiang-He Lei; Barry R Bochner
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

3.  Identification of toxemia in patients with Clostridium difficile infection.

Authors:  Hua Yu; Kevin Chen; Jianguo Wu; Zhiyong Yang; Lianfa Shi; Lydia L Barlow; David M Aronoff; Kevin W Garey; Tor C Savidge; Erik C von Rosenvinge; Ciaran P Kelly; Hanping Feng
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

4.  Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.

Authors:  Tanya M Monaghan; Adrian Robins; Alan Knox; Herbert F Sewell; Yashwant R Mahida
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

5.  Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells.

Authors:  Jinyu Shan; Ananthi Ramachandran; Anisha M Thanki; Fatima B I Vukusic; Jakub Barylski; Martha R J Clokie
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.